Roundtable on biosimilars with European regulators and medical societies, Brussels, Belgium, 12 January 2016

GaBI Journal

Volumn 5, Issue 2, 2016, Pages 74-83

  Annese, Vito ^a   Avendaño Solá, Cristina ^a   Breedveld, Ferdinand ^a   Ekman, Niklas ^a   Giezen, Thijs J ^a   Gomollón, Fernando ^a   Kurki, Pekka ^a   Kvien, Tore Kristian ^a   Laslop, Andrea ^a   Puig, Lluís ^a   Thorpe, Robin ^a   Weise, Martina ^a   Wolff Holz, Elena ^a  

^a Finnish Medicines Agency   (Finland)

Author keywords

Biologicals biosimilars; Extrapolation; Interchangeability; Medical societies; Prescribers; Regulators

Indexed keywords

BIOSIMILAR AGENT; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; FILGRASTIM; HUMAN GROWTH HORMONE; INFLIXIMAB; INSULIN GLARGINE; PEGFILGRASTIM; RECOMBINANT ERYTHROPOIETIN;

ANKYLOSING SPONDYLITIS; ARTICLE; BELGIUM; BIOCOMPATIBILITY; BREAST CANCER; CONFLICT OF INTEREST; COST CONTROL; DRUG EFFICACY; DRUG MANUFACTURE; DRUG RESEARCH; DRUG SAFETY; DRUG SUBSTITUTION; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; EUROPE; FEBRILE NEUTROPENIA; HEALTH CARE ACCESS; HEALTH CARE ORGANIZATION; HUMAN; IMMUNOGENICITY; INTERPERSONAL COMMUNICATION; MEDICAL DECISION MAKING; MEDICAL EXPERT; MEDICAL INFORMATION; MEDICAL SOCIETY; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; PATIENT CARE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHYSICIAN ATTITUDE; POSTMARKETING SURVEILLANCE; PROFESSIONAL PRACTICE; UNSPECIFIED SIDE EFFECT;

EID: 84997639519     PISSN: 20336403     EISSN: 20336772     Source Type: Journal    
DOI: 10.5639/gabij.2016.0502.019     Document Type: Article

References (5)

1. Schneider CK. Biosimilars in rheumatology: the wind of change. Ann Rheum Dis. 2013 Mar;72(3):315-8.
2. Schiestl M, Stangler T, Torella C, Cepeljnik T, Toll H, Grau R. Acceptable changes in quality attributes of glycosylated biopharmaceuticals. Nat Biotechnol. 2011;29(4):310-2.
3. Weise M, et al. Biosimilars: the science of extrapolation. Blood. 2014;124(22):3191-6.
4. Flodmark CE, et al. Switching from originator to biosimilar human growth hormone using dialogue teamwork: single-center experience from Sweden. Biol Ther. 2013;3:35-43.
5. GaBI Online-Generics and Biosimilars Initiative. Norwegian study may be slowing adoption of biosimilar infliximab [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2016 Apr 21]. Available from: www.gabionline.net/Biosimilars/News/Norwegian-study-may-be-slowing-adoption-of-biosimilar-infliximab